Location History:
- Hershey, PA (US) (2014 - 2016)
- Philadelphia, PA (US) (2016 - 2017)
- Ann Arbor, MI (US) (2017 - 2019)
- Cambridge, MA (US) (2017 - 2024)
- New Haven, CT (US) (2019 - 2024)
Company Filing History:
14 out of 14 
7 out of 1,220 
2 out of 832,891 Years Active: 2014-2024
Title: **Innovative Contributions of Joshua E. Allen in Cancer Treatment**
Introduction
Joshua E. Allen, a distinguished inventor based in New Haven, CT, has significantly impacted the field of cancer treatment through his innovative work. With a remarkable portfolio of 20 patents, his research primarily focuses on novel therapeutic methods targeting complex conditions such as gliomas.
Latest Patents
Among his latest patents is the development of Imipridones for gliomas. This innovation involves selectively modulating Class A G protein-coupled receptors (GPCRs), specifically the D2-like subfamily of dopamine receptors, which are pivotal in addressing cancers, including midline gliomas characterized by histone H3 mutations. His patent outlines methods for determining the responsiveness of subjects to treatment regimens, as well as assessing the effectiveness of such therapies through imipridone administration.
Another noteworthy patent attributed to Allen pertains to the compound 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one. This patent describes methods for utilizing this compound, its analogs, and pharmaceutically acceptable salts in therapeutic treatments, particularly for cancer, effectively broadening the scope of available treatment options for patients.
Career Highlights
Joshua E. Allen has lent his expertise to esteemed organizations, including Oncoceutics, Inc. and The Penn State Research Foundation. His contributions to these institutions underline his commitment to advancing cancer research and developing innovative therapies that can potentially transform treatment outcomes for patients.
Collaborations
Throughout his career, Allen has collaborated with notable figures in the field, such as Martin Stogniew and Wafik S. El-Deiry. These collaborations have enriched his research endeavors, fostering an environment conducive to innovation and advancement in cancer therapeutics.
Conclusion
Joshua E. Allen stands out as a visionary inventor whose patents facilitate significant progress in cancer treatment. His innovative contributions redefine therapeutic possibilities, exemplifying the profound impact that dedicated inventors can have in the realm of medicine.